Table 3.
Summary of tumour sample immunohistochemical analyses and correlation with PFS and OS.
| CON (n = 65) | SEQ (n = 63) | HR, 95% CI for PFS | HR, 95% CI for OS | |
|---|---|---|---|---|
| Tumour grade | ||||
| Well differentiated/moderately differentiated | 2 (4%)/38 (67%) | 2 (4%)/38 (72%) | 0.65, 0.41–1.04 | 0.86, 0.53–1.39 |
| Poorly differentiated | 17 (30%) | 13 (24%) | 0.77, 0.35–1.70 | 1.08, 0.50–2.33 |
| Unknowna | 8 | 10 | ||
| Prognostic: p log rank = 0.41 (PFS), 0.12 (OS) | ||||
| CDA expression—tumour epithelium | ||||
| Negative/weakly positive/positive | 3 (6%)/8 (15%)/ 25 (47%) | 0/10 (19%)/25 (48%) | 0.91, 0.56–1.48 | 1.07, 0.65–1.76 |
| Strongly positive | 17 (32%) | 17 (33%) | 0.31, 0.13–0.70 | 0.74, 0.36–1.56 |
| Unknowna | 12 | 11 | ||
| Prognostic: p log rank = 0.24 (PFS), 0.88 (OS) | ||||
| CDA expression—stromal cells | ||||
| Weakly positive/positive | 14 (34%)/22 (54%) | 17 (40%)/21 (50%) | 0.74, 0.46–1.20 | 1.10, 0.67–1.79 |
| Strongly positive | 5 (12%) | 4 (10%) | 0.73, 0.17–3.07 | 1.49, 0.33–6.81 |
| Unknowna | 24 | 21 | ||
| Prognostic: p log rank = 0.12 (PFS), 0.48 (OS) | ||||
| Presence of tumour stroma | ||||
| None/minimal | 11 (19%)/14 (24%) | 7 (13%)/24 (45%) | 0.56, 0.30–1.03 | 0.79, 0.45–1.38 |
| Moderate/extensive | 19 (33%)/14 (24%) | 13 (24%)/9 (17%) | 0.60, 0.34–1.06 | 0.85, 0.47–1.53 |
| Unknowna | 7 | 10 | ||
| Prognostic: p log rank = 0.027 (PFS), 0.023 (OS) | ||||
aUnknown = insufficient tumour sample to analyse.